Latest News

  • TapImmune to Present at the 3rd Annual Growth Capi...

    JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines...

    Read more

  • TapImmune Announces Phase 2 Ovarian Cancer Trial S...

    JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in...

    Read more

  • TapImmune Completes GMP Manufacturing and Release ...

    Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage...

    Read more

  • Join TapImmune at Jacksonville’s Immunothera...

    UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership...

    Read more

  • Experts say research shows promise for a breast ca...

    03/31/16 Medicine By Kathleen McGrory, Times staff writer There are vaccines to help the body fight off measles, mumps and the flu. But breast cancer? That’s exactly the technology a...

    Read more

  • Update with TapImmune, Inc. – Discusses Targ...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

    LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D.,...

    Read more

  • StockNewsNow.com Publishes New SNNLive Video Inter...

      LOS ANGELES, CA–(Posted on Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn...

    Read more

  • TapImmune to Present at 28th Annual ROTH Conferenc...

      JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based...

    Read more

  • TapImmune Inc (OTCMKTS:TPIV) Tapping Into Big Thin...

    TapImmune Inc (OTCMKTS:TPIV) has emerged as one of the most exciting names on the OTC markets. TPIV is on the verge of some huge developments in the biotech space. We think 2016 could be...

    Read more

  • TapImmune Receives Notice of Allowance on U.S. Pat...

    Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc....

    Read more

  • TapImmune Inc. gets fast track status from FDA for...

    TapImmune Inc., a Jacksonville-based immunotherapy company, has received fast track status from the U.S. Food & Drug Administration to study the use of its vaccine TPIV 200 to treat a certain...

    Read more

  • TapImmune Sponsors 26.2 With DONNA Marathon for Br...

      Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016   JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology...

    Read more

  • TapImmune: Proud Supporter of World Cancer Day, F...

    World Cancer Day is marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. World Cancer Day was founded by the Union for International Cancer...

    Read more

  • TapImmune Granted Fast Track Designation by U.S. F...

    TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

    Read more

  • TapImmune Appoints Frederick G. Wasserman to its B...

    TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of...

    Read more

  • TapImmune to Present at Biotech Showcase 2016 in S...

    JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune moves forward with new drugs...

    By Mark Basch, Contributing Writer TapImmune Inc. is a pharmaceutical research company that may never make a big splash in Jacksonville, as far as local employment and operations go.However, the...

    Read more

  • We Are Back!

    We regret that due to circumstances beyond our control our website was offline over the weekend and yesterday.    We are in the process of re-engineering and updating our website to better serve...

    Read more

  • Patrick Yeramian Multi-Epitope Vaccine Granted Orp...

    The orphan designation for TPIV 200 was based on findings from a phase I study, which were electronically published in conjunction with the 2015 ASCO Annual Meeting. In the study, treatment with the...

    Read more

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

JACKSONVILLE, Florida, December 7, 2015 /PRNewswire/

TapImmune (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015 San Antonio Breast Cancer Symposium, which will be held in San Antonio, Texas on December 8 – 12, 2015.

Data will be presented at the poster session, “Treatment: Immunotherapy” on Thursday, December 10, from 7:30 am to 9:00 am. The poster titled, “Robust generation of T-cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine,” was co-authored by Dr. Wilson, Dr. Knutson, Dr Degnim and other researchers from the Mayo Clinic in Rochester, MN.

The poster presentation will include previously unpublished data from a concluded Phase 1 trial conducted at the Mayo Clinic on a T-cell stimulating vaccine (TPIV 100) for the indication of HER2/neu breast cancer.  TapImmune has the Exclusive Option to license this technology from the Mayo Clinic.  The percent of patients that responded with augmented T cell immunity to the four peptide antigens contained in the vaccine was high for each peptide ranging from 68-88%, which led to the 90% of the patients augmenting T cells that recognized naturally processed HER2 antigen.  ”This presentation will present evidence of a robust and significant immune response using antigens designed to target HER2/neu epitopes known to be important targets in a variety of cancers. These are compelling data that has made us excited about initiating development efforts towards a Phase 2 program with this product” stated Dr. Wilson

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website athttp://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements.

Contacts:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

 

Life Sciences Intellectual Property Review

TapImmune featured in Life Sciences Intellectual Property Review

LSIPR logo
Page 1 of 212